Ckap2 Regulates Aneuploidy, Cell Cycling, and Cell Death in a p53-Dependent Manner

Katsuya Tsuchihara,1 Valentina Lapin,1 Christopher Bakal,2,3 Hitoshi Okada,1 Lauren Brown,2,3 Masami Hirota-Tsuchihara,1 Kathrin Zaugg,1,3 Alexandra Ho,1 Annick Itie-YouTen,1 Marees Harris-Brandts,2 Robert Rottapel,2,3 Christopher D. Richardson,2,3 Samuel Benchimol,2,3 and Tak Wah Mak1,2,3

Abstract
We used DNA microarray screening to identify Ckap2 (cytoskeleton associated protein 2) as a novel p53 target gene in a mouse erythroleukemia cell line. DNA damage induces human and mouse Ckap2 expression in a p53-dependent manner and p53 activates the Ckap2 promoter. Overexpressed Ckap2 colocalizes with and stabilizes microtubules. In p53-null cells, overexpression of Ckap2 induces tetraploidy with aberrant centrosome numbers, suggesting disturbed mitosis and cytokinesis. In p53-competent cells, Ckap2 does not induce tetraploidy but activates p53-mediated cell cycle arrest and apoptosis. Our data suggest the existence of a functional positive feedback loop in which Ckap2 activates the G1 tetraploidy checkpoint and prevents aneuploidy. (Cancer Res 2005; 65(15): 6685-91)

Introduction
Inactivation of the tumor suppressor p53 is commonly associated with tumorigenesis. p53 prevents the proliferation of aberrant cells by regulating the cell cycle and apoptosis. Once activated by DNA damage, p53 translocates into the nucleus and induces the transcription of target genes harboring p53-binding sites. Tumor-derived mutant p53 proteins lack transactivation ability, confirming the importance of p53 target genes in tumor prevention (1). Whereas many p53 target genes are known, transcriptomic and bioinformatic studies suggest that p53 induces additional genes important for tumor suppression (2, 3).

Aneuploidy is linked to genetic instability and malignant tumor progression. A frequent precursor of aneuploidy is tetraploidy, which arises from mitotic errors induced by cytoskeletal perturbation or excess mitotic kinases. Although the mechanism is not fully elucidated, p53 is frequently activated in tetraploid cells and p53 engages the G1 tetraploidy checkpoint and prevents aneuploidy. Through DNA microarray screening of a mouse erythroleukemia cell line in which the p53 gene carries a temperature-sensitive mutation, we identified Ckap2 (cytoskeleton-associated protein 2; ref. 7) as a novel p53 target gene. Tumor-specific overexpression of human homologue of Ckap2 has been reported in B-cell lymphoma and gastric cancer. However, biological function of this gene product has not been identified (7–9). In this study, we showed that Ckap2 protein associates with and stabilizes microtubules, and Ckap2 overexpression induces tetraploidy in the absence of p53. In p53-competent cells, Ckap2 enhances wild-type (WT) p53 activity and triggers G1 arrest and apoptosis in a p53-dependent manner.

Materials and Methods
cDNA microarray
The mouse erythroleukemia cell line DP16.1 and its derivative DP16.1/p53ts (which bears a temperature-sensitive mutation of p53 that inactivates it at 37°C) were cultured in α-MEM supplemented with 10% FCS for 6 hours at 37°C or 32°C. Total RNA was extracted using the RNaseq total RNA extraction kit (Qiagen, Valencia, CA). Synthesis of cDNA probes using Cy3 and Cy5, hybridization of these probes to the mouse GEMI cDNA microarray, and signal intensity analyses were done using IncyteGenomics, Inc. (Palo Alto, CA).

Prediction of promoter and p53-binding sites.
Mouse and human genomic DNA sequences were obtained from National Center for Biotechnology Information Entrez Gene (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene). Promoter sequences were predicted using WWW Promoter Scan program (http://www-bimas.cit.nih.gov/molbio/pscan/; ref. 10). Potential p53-binding sites were sought using TFBIND (http://tfbind.hgc.jp/; ref. 11).

Cell culture and DNA transfection.
E14K embryonic stem cells (129/Oa) were maintained on 1% gelatin-coated dishes in DMEM supplemented with leukemia inhibitory factor, 15% FCS, and L-glutamine. The human cell lines HCT116 p53(−/−) were generously provided by Dr. B. Vogelstein (Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD) and maintained in McCoy5A medium supplemented with 10% FCS and L-glutamine. Transient transfections were done using LipofectAMINE 2000 (Invitrogen, Carlsbad, CA).

Northern blotting.
Total RNA was isolated using the RNeasy total RNA extraction kit (Qiagen) and samples (10 μg) were fractionated, probed, and visualized using standard protocols.

Western blotting.
Total cell lysates (10-20 μg) were prepared, fractionated, and blotted according to standard protocols. Anti-Ckap2 antiserum was raised in rabbits against a purified 6× histidine-tagged Ckap2 fusion protein and affinity-purified on GST-Ckap2 Sepharose beads. Other antibodies were as follows: rabbit anti-mouse p53 (CM5; Novoceastra, Newcastle upon Tyne, United Kingdom); mouse anti-human p53 (Ab-6); anti-human p21WAF1 (Ab-4); anti-human p21(138-145) (Ab-3); all from Calbiochem, Darmstadt, Germany; and rabbit anti-actin (Sigma, St. Louis, MO).

Mammalian expression vectors.
Mouse expressed sequence tags (EST) clone BF168983 contained the full-length Ckap2 cDNA sequence. Human EST clone BU178846 contained the full-length Ckap2 cDNA sequence. These EST clones have been subcloned into the pCMV-SPORT6 vector system for expression.

Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/). Requests for reprints: Tak W. Mak, The Campbell Family Institute for Breast Cancer Research, 620 University Avenue, Suite 706, Toronto, Ontario, Canada M5G 2C1. Phone: 416-946-2234; Fax: 416-204-5300; E-mail: tmak@uhnres.toronto.ca.

© 2005 American Association for Cancer Research.
vector (Invitrogen) and used for mouse Ckap2 (pSPORT6-Ckap2) or human Ckap2 (pSPORT6-Ckap2) expression in mammalian cells. For expression of full-length Ckap2 bearing a COOH-terminal enhanced green fluorescent protein (EGFP) tag, a full-length Ckap2 cDNA fragment without a stop codon was amplified by PCR from BF166983 and subcloned into the EGFP expression vector pBIIQ5 (Biogenex, Carlsbad, CA) to generate pBIIQ5-Ckap2 (1-648). A series of deletion mutant cDNAs were amplified by PCR using pBIIQ5-Ckap2 (1-648) as a template, and subcloned into pQBI25.

Luciferase assays. DNA fragments derived from the upstream region of the Ckap2 and Ckap2 genes were amplified by PCR from the 129/SvEVTac mouse phage artificial chromosome clone 638C11 (BACPAC Resources Center, Children’s Hospital Oakland Research Institute, Oakland, CA), and genomic DNA of HCT116 cells, respectively. Amplified DNA fragments were subcloned into either the pGL3-Basic or pGL3-Promoter vectors (Promega, Madison, WI) to generate pro-Luc constructs as detailed in Supplementary Methods. These constructs were cotransfected into HCT116 p53+/− cells with either empty pcDNA3 vector or pcDNA3 vector expressing p53. Luciferase activity was measured and normalized as described in Supplementary Methods.

Chromatin immunoprecipitation. Chromatin immunoprecipitation (ChIP) assays were done using the Acetyl-Histone H3 ChIP Assay Kit (Upstate Biotechnology, Charlottesville, VA). Anti-mouse p53 (CM5) was used for immunoprecipitation. PCR amplifications of the promoter regions of the Ckap2 gene containing the consensus p53-binding sequences (−359 to −159 and −409 to −186), and of intron 1 that lacks a p53-binding site (−238 to +405), were done on immunoprecipitated chromatin using specific primers and conditions as detailed in Supplementary Methods.

Immunofluorescence microscopy. HCT116, HCT116 p53+/−, and NIH3T3 cells were transfected with pQBI25-Ckap2 (1-648) and its variants. At 48 hours posttransfection, cells were preextracted and fixed as described (12). The following primary and secondary antibodies were used: mouse anti-bovine tubulin (Invitrogen) mouse monoclonal anti-acetyl-tubulin (6-11B-1, Sigma), mouse monoclonal anti-γ-tubulin (GTU-88, Sigma), and Alexa Fluor 594 goat anti-mouse IgG (Molecular Probes). Images were obtained using an Olympus IX70 inverted microscope and Deltavision Deconvolution Microscopy software (Applied Precision, Issaquah, WA).

Reverse transcription-PCR. Mouse Ckap2, p21(WAF1), and actin in DP16.1 and mouse embryonic stem cells were detected by reverse transcription-PCR (RT-PCR). Primers and conditions are detailed in Supplementary Methods. HCT116 cells were transfected with pQBI25-Ckap2 (1-648), pQBI25-Ckap2 (1-382), or pQBI25 along with 0.2 µg of a vector expressing the puromycin resistance gene (pBabe-puro; ref. 13). Transfected cells were selected by 48 hours culture in 10 µg/mL puromycin. Total RNA was purified from 1 × 10⁶ cells using Superscript III CellsDirect cDNA Synthesis Kit (Invitrogen). Synthesized cDNA (1%) was subjected to RT-PCR using previously described primer sets and PCR conditions (14).

5-Bromo-2-deoxyuridine incorporation. 5-Bromo-2′-deoxyuridine (BrdUrd) incorporation was done using the BrdUrd Labeling and Detection Kit 1 (Roche, Basel, Switzerland) with some modifications. HCT116 and HCT116 p53+/− cells were plated on glass slides and transfected with pQBI25-Ckap2 (1-648), pQBI25-Ckap2 (1-382), or pQBI25. Transfected cells were labeled with BrdUrd 48 hours after transfection. Cells were fixed with 2% paraformaldehyde and permeabilized with 0.1% Triton X-100. Incorporated BrdUrd was visualized using anti-BrdUrd and Alexa Fluor 594 anti-mouse IgG. At least 100 cells were examined per transfection.

Cell death and apoptosis assay. For apoptosis, TUNEL assays were done using the In Situ Cell Death Detection Kit (Roche). For cell death, HCT116 cells (5 × 10⁶) were plated in six-well plates and transfected with 0.8 µg Ckap2 expression vectors and 0.2 µg EGFP expression vector. Transfected cells were observed by fluorescence microscope 48 hours after transfection. Cellular morphology was examined and percentages of GFP-positive cells with aberrant versus normal morphology were calculated.

Results

Ckap2 is a p53 target gene. The mutant p53 adopts a WT conformation at 32°C and induces transcription of downstream genes in DP16.1/p53ts cells (15). The transcriptomes of DP16.1/p53ts cells cultured at 37°C versus 32°C were screened with the mouse EST microarray chip. Using a cutoff ratio of 2.3 and a fold up-regulation minimum of 2.4, we isolated 32 ESTs induced by p53. Northern blotting showed that 10 were independent novel p53 targets (data not shown), including EST W11380, which represented a partial murine Ckap2 cDNA (7).

To confirm that p53 induced Ckap2, we examined mRNA and protein expression in DP16.1/p53ts cells using full-length Ckap2 cDNA for Northern blotting, RT-PCR, and rabbit antisem against full-length recombinant Ckap2 protein for Western blotting. Both mRNA and protein levels of Ckap2 were increased in DP16.1/p53ts cells (but not the parental p53−/−/DP16.1 cells) shifted from 37°C to 32°C (Fig. 1A). We then treated WT mouse embryonic stem cells with various DNA-damaging agents. Ckap2 mRNA and protein were induced by γ-irradiation and etoposide treatment, but not by UV irradiation (Fig. 1B). The control p53 target gene p21(WAF1) was induced by all stimuli tested.

Human Ckap2 undergoes alternative splicing that generates two major transcripts and proteins in multiple tissues and cell lines (8). We used our rabbit anti-Ckap2 antisem (which cross-reacts with both human Ckap2 proteins) to investigate whether human Ckap2 proteins are also up-regulated by p53. The human colon cancer cell line HCT116, and its derivative HCT116 p53−/− (in which both p53 alleles are deleted), were treated with γ- or UV irradiation. Both Ckap2 proteins were induced in HCT116 but not in HCT116 p53−/− cells (Fig. 1C).

p53 transactivates the Ckap2 promoter. To determine whether p53 up-regulates Ckap2 via transactivation, we cloned a genomic DNA fragment containing the mouse Ckap2 gene from a mouse phage artificial chromosome library. The upstream region of the Ckap2 gene was analyzed with a promoter prediction program. A site 300 bp upstream of Ckap2 exon 1 appeared to contain a TATA-less promoter (Fig. 1D) with a highly conserved p53-binding site. This site matched the consensus p53-binding site (16) at 18 of 20 bp with no spacer between the two half sites. In the human Ckap2 locus, a putative p53-binding site was found 7 kb upstream of Ckap2 exon 1 (Fig. 1D).

We used ChIP assays to investigate whether p53 protein could bind to the predicted p53-binding site in the Ckap2 promoter. Lysates of DP16.1/p53ts cells grown at 32°C for 8 hours were immunoprecipitated using anti-p53 antibody followed by PCR amplification. Only the region of Ckap2 promoter containing the p53-binding site was specifically amplified from the genomic DNA fragment coimmunoprecipitated with p53 protein (Fig. 1E).

To determine whether p53 could induce Ckap2 promoter activity, a series of DNA fragments upstream of Ckap2 were subcloned into a luciferase reporter gene expression vector (free of enhancers or promoters) and transfected into HCT116 p53−/− cells that also received, or did not receive, a plasmid conferring p53 expression. Reporter constructs containing the putative Ckap2 promoter (−440 Ckap2-pro-Luc, −294 Ckap2-pro-Luc, −265 Ckap2-pro-Luc) showed detectable luciferase activity in p53−/− cells, suggesting that the basal activity of the Ckap2
Figure 1. Ckap2 is transactivated by p53. A, p53 dependence of Ckap2 mRNA and protein induction in mouse erythroleukemia cells. DP16.1 (control) and DP16.1/p53ts (p53ts) cells were temperature-shifted to activate p53 in the latter. Left, Northern blot of total RNA (10 μg) prepared from cells grown for 6 hours at 37°C or 32°C. Probes were cDNAs specific for Ckap2, p21Waf1, or actin. Middle, RT-PCR detection of Ckap2, p21Waf1, or actin of total RNA (1 μg) prepared from the same samples of Northern blot. Right, Western blot of total protein extracted from DP16.1 and DP16.1/p53ts cells grown at 37°C or 32°C for 8 hours. Detection was with anti-Ckap2, anti-p21Waf1, and antiactin antibodies.

B, induction of endogenous Ckap2 by DNA damage. WT mouse embryonic stem cells were exposed to 50 μmol/L etoposide, 50 mJ/cm² UV irradiation, or 3 or 10 Gy γ-irradiation and incubated for 6 or 8 hours for total RNA or total protein preparations, respectively. Probes for Northern blotting (left), RT-PCR (middle), and antibodies for Western blotting (right) were as for (A) and anti-p53. C, p53 dependence of CKAP2 induction in human cells. Western blot of total protein extracted from HCT116, HCT116 p53−/−, and MCF-7 cells treated with 10 Gy γ-irradiation or 50 mJ/cm² UV irradiation. Both splice variants of CKAP2 protein were detected by the cross-reacting anti-Ckap2 antibody.

D, structure of the upstream regions of the mouse Ckap2 (top) and human CKAP2 (bottom) loci. A TATA-less promoter (bold arrow) appears 294 nucleotides upstream of Ckap2 exon 1. The potential p53-binding site (bold lettering) is shown beneath the p53 consensus binding site. Arrowheads indicate the PCR primers used for ChIP analysis. DNA fragments (thin solid arrows) from the Ckap2 upstream region with (−440 to +294 Ckap2-pro) or without (−265 Ckap2-pro) the p53-binding site were used to generate the luciferase (Luc) reporters (−440 Ckap2-pro-Luc, −294 Ckap2-pro-Luc, or −265 Ckap2-pro-Luc), respectively. Similarly, fragments containing (−265/−284) or lacking (−265/−284) the p53-binding site were subcloned in front of the SV40 promoter (thin dotted arrows) to generate CKAP2-enh-SV40-pro-Luc. A DNA fragment (−7,403 to +7,184) containing the putative p53-binding site of human CKAP2 was subcloned in front of SV40-Luc to generate CKAP2-enh-SV40-pro-Luc.

E, ChIP assay of p53 DNA-binding activity in DP16.1/p53ts cells. Cells were cultured at 32°C or 37°C for 6 hours. Cross-linked and fragmented p53-DNA complexes were immunoprecipitated with either anti-p53 antibody (p53 IP +) or normal rabbit serum (p53 IP −). Precipitated DNA was subjected to PCR using primers that amplified either promoter fragments containing the p53-binding site (+359 to +159 and +409 to +186), or the intron 1 region lacking the p53-binding site (+238 to +405). Unprecipitated genomic DNA was the loading control.

F, luciferase activities of deletion mutants with or without Ckap2 or CKAP2 p53-binding site following transfection into HCT116 p53−/− cells with (open columns) or without (solid columns) the p53 expression plasmid. Luc activities (FL) were normalized to the activity of simultaneously transfected pRL-TK (RL). Columns, mean FL/RL values (n = 3); bars, SE.
promoter is derived from this region (Fig. 1F). Cotransfection of p53 increased the luciferase activity of constructs containing the putative p53-binding site (−440 Ckap2-pro-Luc, −294 Ckap2-pro-Luc) but not a construct lacking this site (−265 Ckap2-pro-Luc). Cotransfection of p53 increased the luciferase activity of constructs containing the putative p53-binding site (−/C0 440 Ckap2-pro-Luc, −/C0 294 Ckap2-pro-Luc) but not a construct lacking this site (−/C0 265 Ckap2-pro-Luc).

Luciferase activity was also induced by chimeric promoters containing the SV40 promoter plus the Ckap2 upstream region or the human CKAP2 enhancer. p53 overexpression enhanced the activity of constructs containing the p53-binding site (−/C0 440−/C0 265).

Figure 2. Overexpressed Ckap2 colocalizes with and stabilizes microtubules. HCT116 p53−/− cells were transfected with the EGFP-Ckap2 (1-648) expression plasmid, cultured for 48 hours, and fixed. Ckap2 expression was detected using an EGFP tag (A and E, green). Microtubules were visualized using anti-α-tubulin antibody (B, red), whereas stabilized microtubules were detected using anti–acetylated tubulin (F, red). Cell nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI; C and G, blue). Merged image shows the colocalization of overexpressed Ckap2 with microtubules (D, yellow). Microtubules were acetylated only in Ckap2-overexpressing cells (H, yellow).

Figure 3. Microtubule-associated Ckap2 induces nuclear abnormalities. A, schematic representation of Ckap2 variants and their association with microtubules (MT). B, localization of Ckap2 deletion mutants. NIH3T3 cells were transfected with EGFP-Ckap2 (1-648), EGFP-Ckap2 (1-467), or EGFP-Ckap2 (1-382), and subcellular distribution was detected by fluorescence microscopy. C, microtubule-associated Ckap2 induces multinucleate cells. HCT116 (p53−/−) or HCT116 p53−/− cells were transfected with the indicated EGFP-Ckap2 deletion mutants or CKAP2. After 48 hours, nuclei were fixed and stained with DAPI and GFP-positive cells showing multiple nuclei were counted. At least 300 cells were examined per transfection. Columns, mean percentage of multinucleate cells (n = 3); bars, SE. D, Ckap2 induces centrosome amplification. HCT116 (p53−/−) or HCT116 p53−/− cells were transfected with EGFP-Ckap2 (1-648) and centrosomes were detected 48 hours later with anti-α-tubulin antibody. Centrosomes in 100 GFP-positive cells were counted per culture. Columns, percentage of total GFP-positive cells that were mononuclear (Nucl = 1) or binuclear (Nucl = 2), and the percentage of each of these groups of cells that contained the indicated numbers of centrosomes. Results shown are the average of duplicate experiments.
SV40-pro-Luc and CKAP2-enh SV40-pro-Luc) but not that of the construct lacking the p53-binding site (−440/−284 SV40-pro-Luc).

**Ckap2 stabilizes microtubules.** Our recombinant mouse Ckap2 protein colocalized with the cytoskeleton (Fig. 2), consistent with previous reports (7–9). Transfected full-length EGFP-Ckap2 was distributed in a fine reticular pattern (Fig. 2A). Comparison of this pattern with patterns generated by α-tubulin immunostaining (Fig. 2B) or nuclear staining (Fig. 2C) suggested that Ckap2 associated with cytoplasmic microtubules. Indeed, the overlay image revealed colocalization of Ckap2 and α-tubulin (Fig. 2D).

Closer examination of microtubules associated with Ckap2 showed a thick bundle-like pattern characteristic of hyperstabilization (Fig. 2A, B, and D). Antiacetylated tubulin antibody, which detects stabilized microtubules (Fig. 2F), bound to tubulin only in Ckap2-expressing cells (GFP-positive cells; Fig. 2E and G), whereas tubulin proteins in untransfected cells (GFP-negative cells; Fig. 2E and G) were not acetylated (Fig. 2H). This microtubule hyperstabilization was p53 independent, because HCT116 cells transfected with the EGFP-Ckap2 showed the same bundle-like microtubules and tubulin acetylation pattern (data not shown). The microtubular localization of Ckap2 was also reproducibly observed in mouse fibroblasts and HeLa cells (data not shown). The tagging of Ckap2 did not influence its localization because HCT116 p53−/− cells transfected with untagged mouse Ckap2 or human CKAP2 cDNA showed the same pattern of microtubular association and hyperstabilization upon staining with anti-Ckap2 antibody (data not shown).

Microtubule-associated Ckap2 induces the formation of multiple nuclei and abnormal centrosome numbers in a p53-dependent manner. The central region of the Ckap2 protein is required for microtubular association (7). We constructed a series of deletion mutants and transfected them into HCT116 and NIH3T3 cells. COOH-terminal deletion mutants lacking up to 202 amino acids (Ckap2 1-588, 1-548, 1-507, and 1-467) showed reticular cytoplasmic localization and thick bundle-like pattern as same as full-length (1-648) Ckap2 (Fig. 3A, B, and H). Double nuclei were not present in Ckap2-expressing HCT116 cells (Fig. 3C). Significantly, the number of binuclear cells was reduced for the one mutant (Ckap2 1-382) that did not associate with microtubules. Thus, binuclear cells appear only when Ckap2 associates with microtubules in the absence of p53.

Costaining of γ-tubulin as a centrosome marker revealed that 90% of the binuclear cells in Ckap2-expressing HCT116 p53−/− cultures showed abnormal centrosome amplification, whereas mononuclear cells had normal centrosome numbers (Fig. 3D; Supplementary Fig. S1). These data imply that extra centrosomes might have arisen as a consequence of aborted cell divisions, which in turn gave rise to tetraploidy, rather than the result of the abnormal centrosome amplification during the S phase (17).

**Ckap2 enhances p53 functions.** Previous reports suggested that p53 is frequently activated by the treatments that induce polyploidy (4, 5). To evaluate the effect of Ckap2 on endogenous p53, EGFP-Ckap2 was transfected into HCT116 cells and endogenous p53 protein and mRNA in total cell lysates were detected by Western blotting and RT-PCR. HCT116 cells expressing full-length Ckap2 (1-648), but not truncated Ckap2 (1-382), showed higher levels of endogenous p53 protein compared with cells transfected with a GFP control vector whereas p53 mRNA level was not changed (data not shown).

Additional etoposide treatment of transfected cells enhances the effect of full-length Ckap2 protein-induced p53 protein level
to disturbed spindle function, which in turn results in cytokinesis defects and ultimately tetraploidy (4). Although "p53-mediated tetraploidy checkpoint" is still an issue of controversy, p53 is frequently activated in cells undergo cytokinesis failure and prevents further proliferation of these cells (17–19). Our study showed that microtubule-associated Ckap2 induces aberrant centrosome numbers and double nuclei formation in the absence of p53. In parallel, Ckap2 overexpression results in endogenous p53 activation, decreased S-phase cells, and increased apoptosis. To test our hypothesis under physiologic conditions, we are developing an antibody that better detects endogenous Ckap2 proteins. RNA interference studies are not an option because cells in which CKAP2 is reduced by RNA interference quickly undergo mitotic catastrophe even in the absence of DNA damage (data not shown).

Ckap2 is highly expressed in gastric cancers and lymphomas but not in normal tissues surrounding these tumors (8, 9, 20). It may seem paradoxical that a target gene of the tumor suppressor p53 would be overexpressed in tumor cells, but there are precedents. The tumor suppressors VHL and RASSF1A interact with tubulin and induce aberrant microtubule stabilization followed by genetic instability (21–23). In addition, the cytokinesis-regulating protein PRC1 was recently identified as a negatively regulated transcriptional target of p53. Activated p53 reduces PRC1 levels, followed by cytokinesis defects and tetraploidy (24). We picture a physiologic feedback loop in which up-regulation of Ckap2, VHL or RASSF1A, or down-regulation of PRC, initially induces tetraploidy, p53 and the tetraploidy checkpoint are subsequently activated such that the abnormal cells are eliminated before they can become aneuploid and promote tumorigenesis. However, the p53 pathway is likely already inactivated in most of tumor cells, eventually overexpressed Ckap2 induces aneuploidy leading to genomic instability and tumorigenesis rather than cell death. Our work suggests that the regulation of microtubule dynamics, as mediated by proteins such as Ckap2, may be vital for tumor suppression.

**Acknowledgments**


Grant support: Terry Fox Cancer Foundation and Canadian Institutes of Health Research grants (T.W. Mak), and a Canadian Institutes of Health Research fellowship (K. Tsuchihara).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Ikuho Hayashi for helpful advice and discussions, Denis Bouchard and Julie Vezina for technical assistance, and Mary Saunders for scientific editing.

References


Ckap2 Regulates Aneuploidy, Cell Cycling, and Cell Death in a p53-Dependent Manner

Katsuya Tsuchihara, Valentina Lapin, Christopher Bakal, et al.


**Updated version**
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/65/15/6685

**Supplementary Material**
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2005/07/26/65.15.6685.DC1

**Cited articles**
This article cites 24 articles, 14 of which you can access for free at:
http://cancerres.aacrjournals.org/content/65/15/6685.full#ref-list-1

**Citing articles**
This article has been cited by 7 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/65/15/6685.full#related-urls

**E-mail alerts**
Sign up to receive free email-alerts related to this article or journal.

**Reprints and Subscriptions**
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

**Permissions**
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.